MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision neurotherapeutics, announced new real-world evidence demonstrating that home-based rehabilitation using its MindMotion platform can substantially increase therapy dose and improve functional outcomes for patients with neurological conditions. The findings, presented at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC, come from a multi-site quality improvement program conducted with Vibra Healthcare and carry significant implications for how neurorehabilitation is delivered after patients leave the clinic.
The program evaluated 177 rehabilitation episodes involving 172 adults, primarily stroke survivors, across four Vibra Healthcare outpatient sites. Participants followed an eight-week home-training regimen using MindMotion GO, with optional extension and periodic therapist supervision. Results showed that patients completed an average of 174 minutes of active training per week, with 84.4% delivered asynchronously—meaning without direct therapist supervision. The additional home training increased total motor-training dose by a median factor of 3.0 compared with usual outpatient therapy alone, based on published assumptions for active practice during usual care. This threefold increase matters because higher therapy dose is consistently linked to better recovery after stroke and other neurological injuries, yet access to intensive therapy is often limited by cost, geography, and clinician shortages.
Feasibility and engagement were also strong: 92.7% of participants successfully completed home setup, and 80.2% achieved the predefined minimum training exposure. Among surveyed participants, 83.8% of satisfaction ratings were positive. Statistically significant pre–post improvements were observed in functional independence (Barthel Index: +10.4 points), balance (Berg Balance Scale: +10.5 points), cognition (SLUMS: +3.4 points), and mobility (Timed Up and Go: −8.8 seconds) among participants with available paired assessments. These gains suggest that high-dose, high-intensity therapy can be effectively replicated at home, potentially extending the benefits of inpatient rehabilitation into the post-acute period.
“Earlier this year, we showed that MindMaze's high-dose, high-intensity therapy, integrated into inpatient rehabilitation, delivers superior functional outcomes in a resource-efficient way,” said Zach Henderson, CEO of MindMaze Therapeutics. “Now, we are demonstrating that this value can extend into the home to address a well-recognized gap in care once patients leave the clinic, in line with the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery. These results, combined with our upcoming MindMotion Lite tablet-based solution, will help make high-quality neurotherapeutics more accessible. Together, these milestones bring us closer to our mission of making neurotherapeutics available at scale.”
The findings arrive as MindMaze prepares to launch Recently announced MindMotion Lite by year-end 2026. That tablet-based solution is designed to deliver the full range of MindMotion GO neurotherapeutic activities with substantially reduced hardware requirements, simplifying home deployment and supporting broader adoption by healthcare providers. By lowering technical and logistical barriers, MindMotion Lite could make high-dose home therapy viable for more patients and health systems.
The full poster, High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program, is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence. The company, whose shares trade under the ticker MMTX, is positioning itself to address the systemic shortage of specialized clinicians with scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. More information is available at www.mindmazetherapeutics.com.
The broader implication is that home-based, technology-enabled rehabilitation may help bridge the gap between inpatient care and long-term recovery, where patients often plateau due to insufficient therapy. If the results hold in broader populations, they could influence clinical guidelines, reimbursement decisions, and how providers allocate rehabilitation resources. For an aging population with growing rates of stroke and neurological disease, scalable home solutions could prove essential to meeting demand without proportional increases in clinical staff. The original release is available at www.newmediawire.com.
